Prior to founding Umoja, Andrew co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. This work led to the development of a program in engineered regulatory T-cells for treatment of inflammatory diseases, the foundational technology for GentiBio. Previously, he was the Chief Scientific Officer of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T-cell platform that is the foundational technology for Allogene, and co-founder of Pregenen Inc., a gene editing and cell-signalling technology company that was acquired by bluebird bio in 2014.
Andrew earned his M.D. from the University of North Carolina School of Medicine, and then completed residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital. Andrew received the American Pediatric Society/Society for Pediatric Research National Young Investigator Award in 2002. He is a member of the American Society for Clinical Investigation and the American Pediatric Society.